<DOC>
	<DOCNO>NCT02655016</DOCNO>
	<brief_summary>This study double-blind , randomize , placebo-controlled ( 2:1 niraparib : placebo ) study patient Stage III IV ovarian cancer . Patients must complete front-line platinum base regimen physician-assessed response Complete Response ( CR ) Partial Response ( PR ) . Stage III patient must visual evidence disease . Additionally , patient must normal &gt; 90 % decrease cancer antigen 125 ( CA-125 ) follow front-line platinum treatment . The study ass efficacy niraparib maintenance treatment , measure PFS .</brief_summary>
	<brief_title>A Study Niraparib Maintenance Treatment Patients With Advanced Ovarian Cancer Following Response Front-Line Platinum-Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<criteria>Main Patient must histologically confirm , advanced ( FIGO Stage III IV ) highgrade predominantly serous endometrioid ovarian cancer , fallopian tube cancer , primary peritoneal cancer complete first line platinum base chemotherapy ( neoadjuvant adjuvant ) Patient must clinical complete response partial response follow completion chemotherapy course . All Stage IV patient eligible , irrespective residual disease , primary interval debulking . Stage III patient require visible residual disease primary surgery . Patients inoperable Stage III IV disease eligible Patient must agree undergo tumor HRD test Patients childbearing potential must negative pregnancy serum test within 72 hour dosed Patient must randomize within 12 week first day last cycle chemotherapy Main Patient mucinous clear cell subtypes epithelial ovarian cancer , carcinosarcoma undifferentiated ovarian cancer Patient undergone 2 debulking surgery Patient receive bevacizumab firstline platinum base therapy Patient pregnant , breastfeeding , expect conceive child , receive study treatment 3 month last dose study treatment Patient prior treatment know PARP inhibitor Patient diagnose and/or treat invasive cancer ( ovarian cancer )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>PARP Inhibitor</keyword>
	<keyword>HRD</keyword>
	<keyword>HRD positive</keyword>
	<keyword>PRIMA</keyword>
	<keyword>PRIMA Clinical Trial</keyword>
	<keyword>PRIMA Study</keyword>
</DOC>